Relay Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Relay Therapeutics, Inc. (RLAY) filed this Current Report on Form 8-K on September 11, 2022. The filing discloses late-breaking interim clinical data from the ReFocus trial for RLY-4008, an investigational oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2). The data was presented at the European Society for Medical Oncology (ESMO) Congress 2022.
Key Financial Metrics
This filing is a Regulation FD disclosure regarding clinical trial results and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The report details interim clinical data based on an August 1, 2022 data cut-off date from the dose escalation and dose expansion phases of the RLY-4008 trial. Key findings include:
- Safety Database: 195 patients total, with 89 treated at the pivotal dose of 70 mg once daily.
- Pivotal Dose Efficacy: Among 17 efficacy-evaluable, FGFR inhibitor-naïve FGFR2-fusion cholangiocarcinoma (CCA) patients, 15 experienced a partial response, resulting in an 88% interim overall response rate (ORR).
- Broader Dose Efficacy: Across all dose levels, 24 out of 38 eligible FGFR inhibitor-naïve patients experienced a partial response, resulting in a 63% interim ORR.
- Safety Profile: No Grade 4 or 5 adverse events were observed. Most adverse events were expected, low-grade, and manageable. Off-target toxicities such as hyperphosphatemia and diarrhea were clinically insignificant.
Outlook, Risks, and Management Commentary
Management intends to host a conference call on September 12, 2022, to discuss the data. The filing includes a cautionary note regarding forward-looking statements, highlighting risks such as:
- Uncertainty regarding whether preliminary results will be predictive of final trial results.
- Potential delays in clinical trials or regulatory interactions.
- Macroeconomic and geopolitical factors affecting operations.
- The possibility that unconfirmed responses may not be confirmed as trials progress.
Investor Verification Checklist
- Verify the confirmation status of the 14 partial responses and the 1 unconfirmed partial response at the pivotal dose.
- Review the full safety data for long-term tolerability beyond the August 1, 2022 cut-off.
- Monitor the timeline for the pivotal cohort enrollment and future regulatory interactions with the FDA.
- Assess the impact of the 88% ORR on the potential commercial value and regulatory pathway for RLY-4008.